178 related articles for article (PubMed ID: 34283175)
21. Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.
Oosten LEM; Chamuleau MED; Thielen FW; de Wreede LC; Siemes C; Doorduijn JK; Smeekes OS; Kersten MJ; Hardi L; Baars JW; Demandt AMP; Stevens WBC; Nijland M; van Imhoff GW; Brouwer R; Uyl-de Groot CA; Kluin PM; de Jong D; Veelken H
Ann Hematol; 2018 Feb; 97(2):255-266. PubMed ID: 29209924
[TBL] [Abstract][Full Text] [Related]
22. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
Goldman S; Smith L; Galardy P; Perkins SL; Frazer JK; Sanger W; Anderson JR; Gross TG; Weinstein H; Harrison L; Shiramizu B; Barth M; Cairo MS
Br J Haematol; 2014 Nov; 167(3):394-401. PubMed ID: 25066629
[TBL] [Abstract][Full Text] [Related]
23. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
Roschewski M; Dunleavy K; Abramson JS; Powell BL; Link BK; Patel P; Bierman PJ; Jagadeesh D; Mitsuyasu RT; Peace D; Watson PR; Hanna WT; Melani C; Lucas AN; Steinberg SM; Pittaluga S; Jaffe ES; Friedberg JW; Kahl BS; Little RF; Bartlett NL; Fanale MA; Noy A; Wilson WH
J Clin Oncol; 2020 Aug; 38(22):2519-2529. PubMed ID: 32453640
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
Kojima Y; Hagiwara S; Uehira T; Ajisawa A; Kitanaka A; Tanuma J; Okada S; Nagai H
Jpn J Clin Oncol; 2014 Apr; 44(4):318-23. PubMed ID: 24558129
[TBL] [Abstract][Full Text] [Related]
25. Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%.
Mohamedbhai SG; Sibson K; Marafioti T; Kayani I; Lowry L; Goldstone AH; Linch DC; Ardeshna KM
Br J Haematol; 2011 Jan; 152(2):175-81. PubMed ID: 21092025
[TBL] [Abstract][Full Text] [Related]
26. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).
Mead GM; Barrans SL; Qian W; Walewski J; Radford JA; Wolf M; Clawson SM; Stenning SP; Yule CL; Jack AS; ;
Blood; 2008 Sep; 112(6):2248-60. PubMed ID: 18612102
[TBL] [Abstract][Full Text] [Related]
27. Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index.
Sýkorová A; Procházka V; Móciková H; Janíková A; Pytlík R; Belada D; Benešová K; Klener P; Ďuraš J; Smolej L; Campr V; Blahovcová P; Trněný M
Neoplasma; 2022 Dec; 69(6):1466-1473. PubMed ID: 36591807
[TBL] [Abstract][Full Text] [Related]
28. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
29. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study.
Galicier L; Fieschi C; Borie R; Meignin V; Daniel MT; Gérard L; Oksenhendler E
Blood; 2007 Oct; 110(8):2846-54. PubMed ID: 17609431
[TBL] [Abstract][Full Text] [Related]
30. Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.
Rampotas A; Wilson MR; Lomas O; Denny N; Leary H; Ferguson G; McKay P; Ebsworth T; Miller J; Shah N; Martinez-Calle N; Bishton M; Everden A; Tucker D; El-Hassad E; Hennessy B; Doherty D; Prideaux S; Faryal R; Hayat A; Keohane C; Marr H; Gibb A; Pocock R; Lambert J; Lacey R; Elmusharaf N; Clifford R; Eyre TA
Br J Haematol; 2021 Jul; 194(2):365-377. PubMed ID: 33959947
[TBL] [Abstract][Full Text] [Related]
31. Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation.
Sun H; Savage KJ; Karsan A; Slack GW; Gascoyne RD; Toze CL; Sehn LH; Abou Mourad Y; Barnett MJ; Broady RC; Connors JM; Forrest DL; Gerrie AS; Hogge DE; Narayanan S; Nevill TJ; Nantel SH; Power MM; Sutherland HJ; Villa D; Shepherd JD; Song KW
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):341-8. PubMed ID: 25656914
[TBL] [Abstract][Full Text] [Related]
32. Primary chest wall Burkitt lymphoma in a case of HIV infection with immune reconstitution.
Jain A; Arun VA; Bal A; Malhotra P
BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34969787
[TBL] [Abstract][Full Text] [Related]
33. Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients.
Xicoy B; Ribera JM; Müller M; García O; Hoffmann C; Oriol A; Hentrich M; Grande C; Wasmuth JC; Esteve J; van Lunzen J; Del Potro E; Knechten H; Brunet S; Mayr C; Escoda L; Schommers P; Alonso N; Vall-Llovera F; Pérez M; Morgades M; González J; Fernández A; Thoden J; Gökbuget N; Hoelzer D; Fätkenheuer G; Wyen C;
Leuk Lymphoma; 2014 Oct; 55(10):2341-8. PubMed ID: 24397614
[TBL] [Abstract][Full Text] [Related]
34. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Bartlett NL; Wilson WH; Jung SH; Hsi ED; Maurer MJ; Pederson LD; Polley MC; Pitcher BN; Cheson BD; Kahl BS; Friedberg JW; Staudt LM; Wagner-Johnston ND; Blum KA; Abramson JS; Reddy NM; Winter JN; Chang JE; Gopal AK; Chadburn A; Mathew S; Fisher RI; Richards KL; Schöder H; Zelenetz AD; Leonard JP
J Clin Oncol; 2019 Jul; 37(21):1790-1799. PubMed ID: 30939090
[TBL] [Abstract][Full Text] [Related]
35. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.
Patte C; Auperin A; Michon J; Behrendt H; Leverger G; Frappaz D; Lutz P; Coze C; Perel Y; Raphaël M; Terrier-Lacombe MJ;
Blood; 2001 Jun; 97(11):3370-9. PubMed ID: 11369626
[TBL] [Abstract][Full Text] [Related]
36. Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trial.
Phillips EH; Burton C; Kirkwood AA; Barrans S; Lawrie A; Rule S; Patmore R; Pettengell R; Ardeshna KM; Montoto S; Paneesha S; Clifton-Hadley L; Linch DC; McMillan AK
EJHaem; 2020 Jul; 1(1):133-141. PubMed ID: 35847742
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates - A multicenter cohort study.
Silva WFD; Garibaldi PMM; Rosa LID; Bellesso M; Clé DV; Delamain MT; Rego EM; Pereira J; Rocha V
Leuk Res; 2020 Feb; 89():106287. PubMed ID: 31864677
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance.
Wight JC; Yue M; Keane C; Johnston A; Linton K; Chin C; Wai SH; Talaulikar D; Gasiorowski R; Cheah CY; Gregory GP; Dickinson M; Minson A; Coombes C; Ku M; Lam S; Hawkes EA
Br J Haematol; 2019 Oct; 187(2):174-184. PubMed ID: 31236941
[TBL] [Abstract][Full Text] [Related]
39. Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience.
Zhang T; Zhang Y; Fei H; Shi X; Wang L; Wang P; Yu J; Shen Y; Feng S
Cancer Cell Int; 2021 Sep; 21(1):498. PubMed ID: 34535141
[TBL] [Abstract][Full Text] [Related]
40. [A comparative study of induction chemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed young medium/high risk diffuse large B cell lymphoma patients].
Wang X; Xia B; Wang CY; Li MZ; Xu W; Yuan T; Tian C; Zhao HF; Yang HL; Zhao ZG; Wang XF; Wang YF; Yu Y; Zhang YZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):117-124. PubMed ID: 30831626
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
